Sars-CoV2
Conditions
Brief summary
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.
Interventions
DIAGNOSTIC_TESTAnti-SARS-CoV2 Serology
A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
OTHERQuestionnaire
Data concerning personal exposure factors are collected in a questionnaire: * Socio-demographic factors: sex, age * Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital * Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures
Sponsors
Direction Centrale du Service de Santé des Armées
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 62 Years
Healthy volunteers
Yes
Inclusion criteria
* Army Training Hospital staff
Exclusion criteria
* Individuals who have already been confirmed Covid-19 positive * Individuals taking preventive anti-Covid-19 therapy or considering participating in anti-Covid-19 therapy study * Individuals on hydroxychloroquine * Pregnant or breastfeeding women * Non-permanent staff during the study period * Individuals identified for a detachment outside the metropole during the study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-SARS-Cov2 seroconversion between Day 0 and Day 60. | From Day 0 to Day 60 | Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample. |
| Anti-SARS-Cov2 seroconversion between Day 0 and Day 30. | From Day 0 to Day 30 | Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample. |
| Anti-SARS-Cov2 seroconversion between Day 30 and Day 60. | From Day 30 to Day 60 | Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between seroconversion and professional factors - job type | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.) |
| Correlation between seroconversion and professional factors - personal protective equipment type | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type |
| Anti-SARS-Cov2 seroprevalence at Day 0. | Day 0 | Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0. |
| Correlation between seroconversion and non-professional factors - wearing of professional equipment | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment |
| Correlation between seroconversion and non-professional factors - respect of barrier gestures | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures |
| Correlation between seroconversion and non-professional factors - contact with infected individuals | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals |
| Correlation between seroconversion and socio-demographic factors - sex | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and sex |
| Correlation between seroconversion and socio-demographic factors - age | Day 60 | Correlation between seroconversion (measured in blood sample) at Day 60 and age |
Countries
France
Outcome results
None listed